Ibuprofen and Dysmenorrhea

M. Yusoff Dawood
The American journal of medicine · 1984 · vol. 77(1) , pp. 87–94 · doi:10.1016/s0002-9343(84)80025-x · PMID:6380282 · W2015005068
article OA: closed CC0 ⤵ 6 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This paper investigated the efficacy of ibuprofen in treating dysmenorrhea, finding it to be an effective analgesic and anti-inflammatory agent for menstrual pain.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Primary dysmenorrhea and secondary dysmenorrhea induced by an intrauterine device are associated with increased production and release of endometrial prostaglandins. The condition may be treated by oral contraceptives, which reduce overall menstrual fluid volume, or by a prostaglandin synthetase inhibitor, such as ibuprofen. Unless the patient wishes to use oral contraceptives for birth control, ibuprofen (Motrin) is the drug of choice because it need only be given for two to three days each cycle, does not suppress the pituitary ovarian axis, and does not cause metabolic alterations. Clinical trials have shown ibuprofen to be highly efficacious, and more effective than indomethacin, aspirin, or propoxyphene, with no or few side effects.

My notes (saved in your browser only)

Condition tags

dysmenorrhea

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (33)

Cited by (6)

Source provenance

crossref
last seen: 2026-08-24T06:27:02.439969+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-09-27T06:17:51.937953+00:00
License: CC0 · commercial use OK